Scott Kellen
2021
In 2021, Scott Kellen earned a total compensation of $546.7K as Chief Financial Officer and Secretary at DiaMedica Therapeutics, a 12% increase compared to previous year.
Compensation breakdown
| Non-Equity Incentive Plan | $90,460 |
|---|---|
| Option Awards | $154,999 |
| Salary | $286,211 |
| Other | $15,050 |
| Total | $546,720 |
Kellen received $286.2K in salary, accounting for 52% of the total pay in 2021.
Kellen also received $90.5K in non-equity incentive plan, $155K in option awards and $15.1K in other compensation.
Rankings
In 2021, Scott Kellen's compensation ranked 10,534th out of 12,415 executives tracked by ExecPay. In other words, Kellen earned more than 15.2% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 10,534 out of 12,415 | 15th |
Division Manufacturing | 4,659 out of 5,505 | 15th |
Major group Chemicals And Allied Products | 2,093 out of 2,375 | 12th |
Industry group Drugs | 1,857 out of 2,096 | 11th |
Industry Pharmaceutical Preparations | 1,378 out of 1,546 | 11th |
Source: SEC filing on April 5, 2022.
Kellen's colleagues
We found two more compensation records of executives who worked with Scott Kellen at DiaMedica Therapeutics in 2021.
News
DiaMedica Therapeutics CEO Rick Pauls' 2023 pay rises 12% to $1.2M
April 4, 2024
DiaMedica Therapeutics CEO Rick Pauls' 2022 pay slips 5% to $1.1M
April 4, 2023
DiaMedica Therapeutics CEO Rick Pauls' 2021 pay jumps 29% to $1.1M
April 5, 2022
DiaMedica Therapeutics CEO Rick Pauls' 2019 pay jumps 105% to $1.5M
April 20, 2020
DiaMedica Therapeutics CEO Rick Pauls' 2018 pay jumps 46% to $734K
April 8, 2019